CytomX Therapeutics, Inc.
Prognozy (mln)
| Okres |
2024-12-31 |
2025-12-31 |
2026-12-31 |
2027-12-31 |
2028-12-31 |
2029-12-31 |
| Przychód (średnia) |
115.66 |
98.28 |
56.81 |
1.00 |
17.96 |
168.71 |
| Przychód Δ r/r |
0.00% |
-15.03% |
-42.20% |
-98.24% |
1696.50% |
839.13% |
| Przychód (min) |
84.70 |
54.31 |
4.00 |
0.48 |
8.55 |
80.33 |
| Przychód (max) |
133.01 |
143.38 |
120.00 |
1.60 |
28.74 |
269.95 |
| EBITDA (średnia) |
-60.74 |
-51.61 |
-29.83 |
-0.53 |
-9.43 |
-88.60 |
| EBIT (średnia) |
-62.79 |
-53.35 |
-30.84 |
-0.54 |
-9.75 |
-91.59 |
| EBIT % |
-54.29% |
-54.29% |
-54.29% |
-54.29% |
-54.29% |
-54.29% |
| Zysk netto (średni) |
-8.80 |
-8.34 |
-30.90 |
-61.58 |
-51.69 |
1.69 |
| Zysk netto % |
-7.61% |
-8.48% |
-54.40% |
-6158.17% |
-287.75% |
1.00% |
| EPS (średnia) |
-0.04 |
-0.10 |
-0.45 |
-0.73 |
-0.61 |
0.02 |
| Liczba analityków (Przychody) |
5 |
5 |
6 |
2 |
1 |
1 |
| Liczba analityków (EPS) |
4 |
5 |
6 |
2 |
1 |
1 |
| symbol |
CTMX |
CTMX |
CTMX |
CTMX |
CTMX |
CTMX |